Cumberland Pharmaceuticals Inc.

    Jurisdiction
    United States
    ISIN
    US2307701092 (CPIX)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €35.89M
    Gross margin
    80.4%
    EBIT
    -€2.32M
    EBIT margin
    -6.5%
    Net income
    -€2.50M
    Net margin
    -7.0%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Jones James N/A +340 $3.43 +$1.17K
    KAZIMI A J Chairman and CEO +340 $3.43 +$1.17K
    Krogulski Kenneth N/A +1.7K $3.43 +$5.87K
    Young Caroline N/A +168 $3.44 +$577.92

    Earnings Calls

    Latest earnings call: May 7, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 503K $2.13M -3.8K Sell

    Add to watchlist

    Notifications